Humana Inc. (NYSE:HUM) had its price target upped by equities research analysts at Deutsche Bank AG from $234.00 to $243.00 in a report issued on Monday. The firm currently has a “hold” rating on the insurance provider’s stock. Deutsche Bank AG’s price target would suggest a potential downside of 1.19% from the company’s current price.

A number of other equities analysts have also issued reports on the stock. Cowen and Company restated an “outperform” rating and set a $230.00 target price on shares of Humana in a research report on Tuesday, April 25th. Leerink Swann increased their price target on Humana from $250.00 to $265.00 and gave the stock an “outperform” rating in a report on Tuesday, May 30th. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $257.00 price target for the company in a report on Thursday, May 25th. BidaskClub downgraded Humana from a “buy” rating to a “hold” rating in a report on Tuesday, June 13th. Finally, UBS AG reaffirmed a “neutral” rating and set a $237.00 price target (up from $205.00) on shares of Humana in a report on Wednesday, June 28th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company’s stock. Humana has a consensus rating of “Hold” and a consensus target price of $243.00.

Humana (HUM) traded up 0.92% during mid-day trading on Monday, reaching $248.19. 525,956 shares of the company’s stock traded hands. The stock has a market capitalization of $35.87 billion, a PE ratio of 20.42 and a beta of 0.91. The stock’s 50 day moving average is $236.19 and its 200-day moving average is $220.68. Humana has a 52 week low of $163.50 and a 52 week high of $251.79.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.08 by $0.41. The company had revenue of $13.53 billion for the quarter, compared to analyst estimates of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same period in the prior year, the firm posted $2.30 earnings per share. On average, equities analysts anticipate that Humana will post $11.42 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/07/humana-inc-nysehum-price-target-raised-to-243-00-at-deutsche-bank-ag.html.

In other Humana news, VP Heidi S. Margulis sold 1,500 shares of the company’s stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $231.96, for a total value of $347,940.00. Following the transaction, the vice president now directly owns 8,150 shares of the company’s stock, valued at approximately $1,890,474. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Brian P. Leclaire sold 4,971 shares of the business’s stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total value of $1,193,040.00. Following the completion of the sale, the senior vice president now owns 14,258 shares of the company’s stock, valued at $3,421,920. The disclosure for this sale can be found here. Corporate insiders own 0.80% of the company’s stock.

Several large investors have recently modified their holdings of HUM. Baldwin Brothers Inc. MA increased its stake in shares of Humana by 2.7% in the first quarter. Baldwin Brothers Inc. MA now owns 67,441 shares of the insurance provider’s stock worth $13,902,000 after buying an additional 1,782 shares during the period. ProShare Advisors LLC increased its stake in shares of Humana by 15.8% in the first quarter. ProShare Advisors LLC now owns 17,297 shares of the insurance provider’s stock worth $3,566,000 after buying an additional 2,356 shares during the period. Capstone Asset Management Co. increased its stake in shares of Humana by 2.0% in the first quarter. Capstone Asset Management Co. now owns 16,805 shares of the insurance provider’s stock worth $3,464,000 after buying an additional 334 shares during the period. CHURCHILL MANAGEMENT Corp purchased a new stake in shares of Humana during the second quarter worth $6,074,000. Finally, Granite Investment Advisors LLC increased its stake in shares of Humana by 12.1% in the first quarter. Granite Investment Advisors LLC now owns 2,410 shares of the insurance provider’s stock worth $497,000 after buying an additional 260 shares during the period. Institutional investors and hedge funds own 99.66% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.